BioLife Solutions BLFS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioLife Solutions's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioLife Solutions's cash & equivalents?
- BioLife Solutions (BLFS) reported cash & equivalents of $22.82M in Q1 2026.
- How has BioLife Solutions's cash & equivalents changed year-over-year?
- BioLife Solutions's cash & equivalents decreased by 65.9% year-over-year, from $66.95M to $22.82M.
- What is the long-term trend for BioLife Solutions's cash & equivalents?
- Over 5 years (2020 to 2025), BioLife Solutions's cash & equivalents has grown at a -18.2% compound annual growth rate (CAGR), from $90.4M to $33.04M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.